National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Pembrolizumab (Keytruda®) for head and neck squamous cell carcinoma. HTA ID: 19051

Pembrolizumab (Keytruda®) is indicated as monotherapy or in combination with platinum and 5-fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a combined positive score.

NCPE Assessment Process Complete
Rapid review commissioned 25/11/2019
Rapid review completed 02/01/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 07/01/2020
Pre-submission consultation with Applicant 24/02/2020
Full submission received from Applicant 28/08/2020
Preliminary review sent to Applicant 16/02/2021
NCPE assessment re-commenced 18/03/2021
Factual accuracy check sent to Applicant 30/04/2021
NCPE assessment re-commenced 10/05/2021
NCPE assessment completed 18/05/2021
NCPE assessment outcome The NCPE recommends that pembrolizumab be considered for reimbursement if cost effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.